Botulinum toxin: Future developments

BJU International

Volumn 102, Issue SUPPL. 1, 2008, Pages 20-22

  De Ridder, Dirk ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Bladder; Botulinum A neurotoxin; Dose; Injection; Prostate; Site

Indexed keywords

4 AMINOPYRIDINE; AMINOGLYCOSIDE; AMINOQUINOLINE DERIVATIVE; BOTULINUM TOXIN; CALCIUM CHANNEL BLOCKING AGENT; CHLOROQUINE; CYCLOSPORIN; GALLAMINE; HYDROCYCHLOROQUINE; PANCURONIUM; PENICILLAMINE; SUXAMETHONIUM; TUBOCURARINE CHLORIDE; BOTULINUM TOXIN A;

CYSTALGIA; DRUG MECHANISM; EATON LAMBERT SYNDROME; HUMAN; INTERSTITIAL CYSTITIS; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; OVERACTIVE BLADDER; PELVIS PAIN SYNDROME; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; URINE RETENTION; BLADDER SPHINCTER; BLADDER WALL; SHORT SURVEY; URINARY TRACT FUNCTION;

ADMINISTRATION, INTRAVESICAL; BOTULINUM TOXIN TYPE A; FEMALE; HUMANS; MALE; NEUROMUSCULAR AGENTS; UROLOGIC DISEASES;

EID: 48149111864     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07823.x     Document Type: Review

References (32)

1. Schurch B, Schmid DM, Stohrer M. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med 2000 342 : 665
2. Stohrer M, Schurch B, Kramer G, Schmid DM, Gaul G, Haun D. Botulinum A-toxin in the treatment of detrusor hyperreflexia in spinal cord injured patients: a new alternative to medical and surgical procedures? Neurourol Urodynamics 1999 18 : 401
3. Schurch B, De Seze M, Denys P et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: Results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005 174 : 196 200
4. Sahai A, Khan M, Smith K, Dasgupta P. Botulinum toxin-A for patients with idiopathic detrusor overactivity: early results from a randomised, double blind, placebo-controlled trial abstract]. International Continence Society Annual Meeting, 2005
5. Dmochowski R, Sand PK. Botulinum toxin A in the overactive bladder. current status and future directions. BJU Int 2007 99 : 247 62
6. Karsenty G, Elzayat E, Delapparent T, St Denis B, Lemieux MC, Corcos J. Botulinum toxin type A injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux. J Urol 2007 177 : 1011 4
7. Karsenty G, Reitz A, Lindemann G, Boy S, Schurch B. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology 2006 68 : 1193 7
8. Comperat E, Reitz A, Delcourt A, Capron F, Denys P, Chartier-Kastler E. Histologic features in the urinary bladder wall affected from neurogenic overactivity - A comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A. Eur Urol 2006 50 : 1058 64
9. Asermely KE, Sterling GH, McCafferty MR, O'Neill JJ. Accelerated communication - synaptophysin is phosphorylated in rat cortical synaptosomes treated with botulinum toxin A. Life Sci 1999 64 : L297 L303
10. Huang W, Foster JA, Rogachefsky AS. Pharmacology of botulinum toxin. J Am Acad Dermatol 2000 43 : 249 59
11. Antunes AA, Srougi M, Coelho RF, Freire GDC. Botulinum toxin for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Nature Clin Prac Urol 2007 4 : 155 60
12. Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: Results of a randomized, placebo-controlled study. Urology 2003 62 : 259 64
13. Chuang YC, Chiang PH, Yoshimura N, Chancellor MB, Hsien KS. Efficacy and length of symptom improvement after botulinum toxin type A injection in BPH patients not correlated with change in prostate volume. J Urol 2007 177 : 610
14. Chuang YC, Chiang PH, Yoshimura N, De Miguel F, Chancellor MB. Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. Bju Int 2006 98 : 1033 7
15. Chuang YC, Yoshimura N, Wu MY et al. Intraprostatic capsaicin injection as a novel model for nonbacterial prostatitis and effects of botulinum toxin A. Eur Urol 2007 51 : 1119 27
16. Chuang YC, Chancellor MB. The application of botulinum toxin in the prostate. J Urol 2006 176 : 2375 82
17. de Seze M, Petit H, Gallien P et al. Botulinum A toxin and detrusor sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur Urol 2002 42 : 56 62
18. Gallien P, Reymann JM, Amarenco G, Nicolas B, De Seze M, Bellissant E. Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. J Neurol Neurosurgery Psychiatry 2005 76 : 1670 6
19. Giannantoni A, Costantini E, Di Stasi SM, Tascini MC, Bini V, Porena M. Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study. Eur Urol 2006 49 : 704 9
20. Kuo HC. Preliminary results of suburothelial injection of botulinum A toxin in the treatment of chronic interstitial cystitis. Urologia Intis 2005 75 : 170 4
21. Kuo HC, Liu HT. Intravesical botulinum toxin a injections reduced nerve growth factor production and bladder pain in chronic interstitial cystitis. J Urol 2007 177 : 42
22. Apostolidis A, Popat R, Yiangou Y et al. Decreased sensory receptors P2X (3) and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005 174 : 977 82
23. Dong M, Yeh F, Tepp WH et al. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006 312 : 592 6
24. Rapp DE, Turk KW, Bales GT, Cook SP. Botulinum toxin type A inhibits calcitonin gene-related peptide release from isolated rat bladder. J Urol 2006 175 : 1138 42
25. Apostolidis A, Dasgupta P, Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 2006 49 : 644 50
26. Smith CP, Vemulakonda VM, Kiss S, Boone TB, Somogyi GT. Enhanced ATP release from rat bladder urothelium during chronic bladder inflammation. Effect of botulinum toxin A. Neurochem Int 2005 47 : 291 7
27. Jeffery ST, Parappallil S, Wang K, Lee F, Morley R, Fynes M. Parameters predicting the response to intradetrusor botulinum a toxin injections in patients with idiopathic detrusor overactivity. Int Urogynecol J 2007 18 : S64
28. Hanna-Mitchell AT, Beckel JM, Barbadora S, Kanai AJ, de Groat WC, Birder LA. Non-neuronal acetylcholine and urinary bladder urothelium. Life Sci 2007 80 : 2298 302
29. Breen LT, Smyth LM, Yamboliev IA, Mutafova-Yambolievea VN. Beta-NAD is a novel nucleotide released on stimulation of nerve terminals in human urinary bladder detrusor muscle. Am J Physiol Renal Physiol 2006 290 : F486 F495
30. Foster KA. The analgesic potential of clostridial neurotoxin derivatives. Expert Opinion Invest Drugs 2004 13 : 1437 43
31. Foster KA, Adams EJ, Durose L et al. Re-engineering the target specificity of clostridial neurotoxins - a route to novel therapeutics. Neurotoxicity Res 2006 9 : 101 7
32. Lim ECH, Seet RCS. Botulinum toxin, Quo Vadis? Med Hypotheses 2007 69 : 718 23